Q3 2023 Earnings Summary
- Strong new product launches, notably Breyna (generic Symbicort), expected to be a significant contributor in 2024 with no anticipated competition, driving revenue growth.
- Effective management of inflationary pressures leading to better-than-expected gross margins, with adjusted EBITDA and free cash flow guidance reaffirmed despite FX headwinds.
- Confidence in generating at least $2.3 billion in free cash flow in 2024 and beyond, with active pursuit of business development opportunities to leverage the global platform and accelerate growth beyond the base business.
- Significant Foreign Exchange (FX) Headwinds: Viatris is experiencing substantial FX pressures due to the strengthening of the U.S. dollar against key currencies like the euro, Japanese yen, and Chinese RMB, impacting revenues by $250 million in 2023, especially concentrated in Q4.
- Dependence on Divestitures and Uncertain Timing of Growth Initiatives: The company's transition to Phase II growth relies on proceeds from planned divestitures and investments in new business development activities, whose timing and success are uncertain, potentially delaying the acceleration of top-line growth beyond the base 3% revenue CAGR target. ,
- Potential Industry-wide Weakness in China: Despite company optimism, there is concern that Viatris may experience weakness in China similar to its peers, which could impact future results in the region due to broader industry challenges.
-
2024 Outlook and Growth Targets
Q: How are businesses trending towards the 3% revenue CAGR in Phase II?
A: Management is confident about 2024, expecting at least $2.3 billion in free cash flow in '24 and beyond, even accounting for inflation and FX headwinds. The base business is stable and growing globally, targeting a 3% revenue CAGR in Phase II, with potential for higher growth through business development. -
Capital Deployment and Divestitures
Q: Are you actively pursuing divestitures and redeploying cash into verticals?
A: The company is actively looking for innovative high-growth assets with predictable revenue streams. While focusing on specific verticals, they remain open to opportunities outside them. Timing is not specified, but they are excited about current opportunities. -
China Business Performance
Q: Why is China performing differently than peers, and are there risks ahead?
A: The China business remains stable despite FX impacts. After VBP cycles, they've shifted focus to private pay channels, finding equilibrium between hospital and private pay. Investing in pipeline products like Yupelri and Dymista, they are confident and optimistic about China's fundamentals. -
Generics Pricing Environment
Q: How is the generics pricing environment, and are trends sustainable?
A: After years, the company sees a longer stretch of stability in generics pricing. Supply disruptions in key molecules continue, but their strong portfolio and supply flexibility provide stability. No concerning trends are observed currently. -
Inflationary Pressures on Costs
Q: Are inflationary pressures on cost of goods affecting margins?
A: Inflation impact exists but is less than anticipated. The team is managing costs well, reflected in better-than-expected gross margins. Full-year gross margin metrics have been raised to 58.75% due to mix and effective cost management. -
FX Impact on Revenue
Q: Why is the FX headwind larger in Q4, lowering revenue guidance?
A: Strengthening of the U.S. dollar against the euro, yen, and RMB since September increased FX impact. About 70% of business is non-U.S. dollar denominated, with 50% from these three currencies. The larger FX impact in Q4 is reflected in the full-year guidance adjustment. -
Breyna (Generic Symbicort) Outlook
Q: How significant will Breyna's contribution be next year?
A: Breyna is expected to be a significant contributor in 2024, with no competition anticipated. The company is pleased with the launch and market share pickup. They are on track to exceed $450 million in new launches, having already achieved $345 million.
Research analysts covering Viatris.